Study of tissue samples in malt lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies tissue samples from people with MALT lymphoma (a type of low-grade lymphoma) to learn more about its biology. It aims to improve understanding of the disease, which could help future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older
- You must have been diagnosed with MALT lymphoma (a slow-growing lymphoma that starts in places like the stomach, eyes, or thyroid) based on a tissue sample taken after January 1, 2000
- You must have a tumor tissue sample (either frozen or preserved in wax) that can be studied
- You must have medical records from your diagnosis and follow-up visits available for review
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a “Mixed Molecular Clinical Index” (MMCI), which combines test results from lymphoma tissue and clinical information. It aims to help better understand how diffuse large B-cell lymphoma behaves and how patients may respond to standard first-line treatment.
This study is looking at people with a rare stomach lymphoma (MALT lymphoma) or people with other stomach conditions. It aims to understand more about the disease and track outcomes over time.
This study is for people who were just diagnosed with marginal zone lymphoma (a slow-growing blood cancer) and haven't started treatment yet. Researchers will collect blood and tissue samples and follow you over time to learn more about the disease.
This study collects and analyzes tumor samples from people with nodal marginal zone lymphoma to better understand the disease and predict outcomes. It may help doctors characterize the lymphoma more accurately using clinical and lab information.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study looks at tissue samples from people who have a more aggressive form of splenic marginal zone lymphoma. It aims to better understand the genetic changes that happen when the disease transforms, which may help doctors predict and treat this condition in the future.
Hear when a new MALT Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.